LG-2527: Difference between revisions
Content deleted Content added
m clean up spacing around commas and other punctuation, replaced: , → , |
|||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{Drugbox |
|||
{{Infobox drug |
|||
| Verifiedfields = |
| Verifiedfields = |
||
| Watchedfields = |
| Watchedfields = |
||
| Line 5: | Line 6: | ||
| IUPAC_name = |
| IUPAC_name = |
||
| image = |
| image = |
||
| width = |
| width = |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| Line 25: | Line 26: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| Line 44: | Line 45: | ||
| ChEBI = |
| ChEBI = |
||
| ChEMBL = |
| ChEMBL = |
||
| synonyms = |
| synonyms = |
||
<!--Chemical data--> |
<!--Chemical data--> |
||
| Line 56: | Line 57: | ||
}} |
}} |
||
'''LG-2527''' is a [[nonsteroidal]] [[progestin]] which was under development by [[Ligand Pharmaceuticals]] and [[Wyeth]] for the treatment of [[menopausal symptoms]] and [[breast cancer]] but was never marketed.<ref name="AdisInsight">https://adisinsight.springer.com/drugs/800007249</ref> It reached the [[preclinical research|preclinical]] stage of development prior to the discontinuation of its development in early 2001.<ref name="AdisInsight" /> |
'''LG-2527''' is a [[nonsteroidal]] [[progestin]] which was under development by [[Ligand Pharmaceuticals]] and [[Wyeth]] for the treatment of [[menopausal symptoms]] and [[breast cancer]], but was never marketed.<ref name="AdisInsight">{{cite web|url=https://adisinsight.springer.com/drugs/800007249|title=LG 2527 - AdisInsight|website=adisinsight.springer.com}}</ref> It reached the [[preclinical research|preclinical]] stage of development prior to the discontinuation of its development in early 2001.<ref name="AdisInsight" /> |
||
==References== |
==References== |
||
{{Reflist}} |
{{Reflist}} |
||
{{Progesterone receptor modulators}} |
{{Progesterone receptor modulators}} |
||
Latest revision as of 01:58, 7 August 2024
| Clinical data | |
|---|---|
| Drug class | Progestin; Progestogen |
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer, but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
References
[edit]- ^ a b "LG 2527 - AdisInsight". adisinsight.springer.com.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |